Personalisation is the biggest lie brands keep telling
Pharma brands need to move beyond surface-level personalisation and focus on measurable impact.
Newsletters and Deep Dive digital magazine
Pharma brands need to move beyond surface-level personalisation and focus on measurable impact.
pharmaphorum spoke with Alexander Seyf, CEO of Autolomous, about the future of AI in Australian biotech.
GLP-1 RA medicine has transformed treatment of metabolic diseases such as obesity and diabetes. We spoke with China's CORXEL about theirs.
Nutrition shapes the biology of ageing; lifestyle determines how that biology is expressed
Consumer device giants are surging into the healthcare arena to make devices cheaper, more compact, and easier for patients to use.
Editor's Picks
Newsletters and Deep Dive
digital magazine